To obtain additional restraints for structural model determination of the p53 TAD2 -FOXO4 FH complex, we determined paramagnetic relaxation enhancements (PREs) for a set of 7 complexes containing spin-labeled (SL) samples ( 15 N-labeled FOXO4 FH + S46C-SL p53 TAD2 , 15 N-labeled FOXO4 FH + Q52C-SL p53 TAD2 , 15 N-labeled p53 TAD2 + Q112C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + D140C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + N145C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + S159C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + S162C-SL FOXO4 FH )
While GHK-Cu is generally well-tolerated in topical research, certain contraindications or precautions should be considered, especially for systemic research or in specific populations: Systemic Research: For systemic applications, GHK-Cu is generally not recommended for subjects who are pregnant, breastfeeding, have active cancer, or suffer from Wilsons disease (a condition involving copper accumulation)
Infused with GHK-Cu Copper Peptides
Results from Combined Metabolic Activators (CMA) trials CMA trials have shown remarkable results
However, an impaired cysteine uptake from the plasma has been proposed secondary to a decrease in plasma GSH
Join now at www.consumerlab.com/join/ As a ConsumerLab.com member, you may print a copy of this report for your personal use
